This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Jerusalem, DATE: BrainsWay Ltd. (TASE: BRIN), a global leader in the advanced non-invasive treatment of brain disorders, today announces that the company will showcase its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD), Major Depressive Disorder (MDD), and other psychiatric and neurological indications at DGPPN 2018 (German Association for Psychiatry, Psychotherapy and Psychosomatics), Booth 32.
BrainsWay will offer demonstrations of its OCD treatment which was recently cleared by the FDA at the BrainsWay exhibit throughout the conference. BrainsWay’s therapy stimulates the brain using a non-invasive approach based on brief magnetic fields. Brainsway will also offer flexible and/or customized business models at Booth 32.
“DGPPN provides a great opportunity for BrainsWay to present Deep TMS non-invasive and effective treatments for Major Depressive Disorder and Obsessive Compulsive Disorder to healthcare providers” said Yaacov Michlin, President and Chief Executive Officer of BrainsWay. “Our live demonstrations of the Deep-TMS helmet for OCD will allow conference visitors to learn more about how they can help their patients who are treatment resistant with this non-invasive and effective treatment.”
BrainsWay’s Deep TMS technology differs from that of other focal TMS devices in that it has broader and deeper applicability and can directly stimulate areas of the brain at a greater depth and breadth than any other TMS device on the market safely and efficiently. While other focal TMS devices are limited to treating major depressive disorder, BrainsWay can now directly target previously unreachable areas of the brain with its proprietary coils, allowing it to effectively treat OCD as well.
“Our Deep TMS technology offers a much-needed treatment option for the millions of adults that suffer from OCD and are resistant to other first-line treatment methods, such as CBT and SSRI medications,” Yaacov Michlin said. “We are encouraged by our results to date and remain dedicated to building on our clinical success.”
OCD is a severe, chronic psychiatric disease characterized by a pattern of obsessive thoughts and compulsive repetitive behaviors, which has a significantly destructive effect on patients’ day-to-day activities. OCD statistics rank the condition in 10th place among all diseases, both physical and mental, that cause disability. Current treatment options include SSRI antidepressant medications, which must be given at very high doses for OCD patients, cognitive-behavioral treatment (CBT), or a combination of these treatment options. OCD is very difficult to treat since many patients do not respond to pharmacologic or CBT treatment, and many have difficulty tolerating the side effects of the pharmacological treatment.
BrainsWay is engaged in the research, development and sales and marketing of a medical system for non-invasive treatment of common brain disorders. The medical system developed and manufactured by the company is based on a unique breakthrough technology called Deep TMS, which can reach significant depth and breadth of the brain and produce broad stimulation and functional modulation of targeted brain areas. In the U.S., the Company’s device has been FDA cleared for the treatment of major depressive disorder (MDD) since 2013, and is now FDA cleared (De-Novo) for the treatment of Obsessive Compulsive Disorder (OCD). BrainsWay is certified by the CE for the following indications: Major Depression, Bipolar Depression, Schizophrenia – Negative Symptoms, Parkinson’s Disease (with anti-Parkinsonian medications), Post-Traumatic Stress Disorder (PTSD), Smoking Cessation, Autism and Asperger’s Disorder, Obsessive Compulsive Disorder (OCD), Multiple Sclerosis (MS), Stroke. Certificate No. 6106G3410141202